BMJ, The

  0959-8146

  1756-1833

  Anh Quốc

Cơ quản chủ quản:  BMJ Publishing Group

Lĩnh vực:
Medicine (miscellaneous)

Các bài báo tiêu biểu

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
- Trang i4919
Jonathan A C Sterne, Miguel A. Hernán, Barnaby C Reeves, Jelena Savović, Nancy D Berkman, Meera Viswanathan, David Henry, Douglas G. Altman, Mohammed Ansari, Isabelle Boutron, James R. Carpenter, An‐Wen Chan, Rachel Churchill, Jonathan J Deeks, Asbjørn Hróbjartsson, Jamie J Kirkham, Peter Jüni, Yoon K. Loke, Theresa D Pigott, Craig Ramsay, Deborah L. Regidor, Hannah R. Rothstein, Lakhbir Sandhu, Pasqualina Santaguida, Holger J. Schünemann, Beverly Shea, Ian Shrier, Peter Tugwell, Lucy Turner, Jeffrey C. Valentine, Hugh Waddington, Elizabeth Waters, George A. Wells, Penny Whiting, Julian P. T. Higgins
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
Tập 349 Số jan02 1 - Trang g7647-g7647 - 2015
Larissa Shamseer, David Moher, Mike Clarke, Davina Ghersi, Alessandro Liberati, Mark Petticrew, Paul G Shekelle, Lesley Stewart
Developing and evaluating complex interventions: the new Medical Research Council guidance
- Trang a1655
Peter Craig, Paul Dieppe, Sally MacIntyre, Susan Michie, Irwin Nazareth, Mark Petticrew
Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide
Tập 348 Số mar07 3 - Trang g1687-g1687 - 2014
Tammy Hoffmann, Paul Glasziou, Isabelle Boutron, Ruairidh Milne, Rafael Perera, David Moher, Douglas G. Altman, Virginia Barbour, H. Macdonald, Michelle Johnston, Sarah E Lamb, Mary Dixon‐Woods, Peter McCulloch, Jeremy C. Wyatt, Angela Chan, Susan Michie
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Tập 346 Số jan08 15 - Trang e7586-e7586 - 2013
Angela Chan, Jennifer Tetzlaff, Peter C Gøtzsche, Douglas G. Altman, Howard Mann, Jesse A. Berlin, Kay Dickersin, A. Hrobjartsson, Kenneth F Schulz, Wendy R. Parulekar, Karmela Krleža-Jerić, Katharine Ker, David Moher
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study
- Trang m1985
Annemarie B Docherty, Ewen M Harrison, Christopher Green, Hayley Hardwick, Riinu Pius, Lisa Norman, Karl Holden, Jonathan M. Read, Frank Dondelinger, Gail Carson, Laura Merson, James Lee, Daniel Plotkin, Louise Sigfrid, Sophie Halpin, Clare Jackson, Carrol Gamble, Peter Horby, Jonathan S. Nguyen‐Van‐Tam, Antonia Ho, Jordan J. Clark, Jake Dunning, Peter Openshaw, J. Kenneth Baillie, Malcolm G. Semple
AbstractObjectiveTo characterise the clinical features of patients admitted to hospital with coronavirus disease 2019 (covid-19) in the United Kingdom during the growth phase of the first wave of this outbreak who were enrolled in the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) World Health Organization (WHO) Clinical Characterisation Protocol UK (CCP-UK) study, and to explore risk factors associated with mortality in hospital.DesignProspective observational cohort study with rapid data gathering and near real time analysis.Setting208 acute care hospitals in England, Wales, and Scotland between 6 February and 19 April 2020. A case report form developed by ISARIC and WHO was used to collect clinical data. A minimal follow-up time of two weeks (to 3 May 2020) allowed most patients to complete their hospital admission.Participants20 133 hospital inpatients with covid-19.Main outcome measuresAdmission to critical care (high dependency unit or intensive care unit) and mortality in hospital.ResultsThe median age of patients admitted to hospital with covid-19, or with a diagnosis of covid-19 made in hospital, was 73 years (interquartile range 58-82, range 0-104). More men were admitted than women (men 60%, n=12 068; women 40%, n=8065). The median duration of symptoms before admission was 4 days (interquartile range 1-8). The commonest comorbidities were chronic cardiac disease (31%, 5469/17 702), uncomplicated diabetes (21%, 3650/17 599), non-asthmatic chronic pulmonary disease (18%, 3128/17 634), and chronic kidney disease (16%, 2830/17 506); 23% (4161/18 525) had no reported major comorbidity. Overall, 41% (8199/20 133) of patients were discharged alive, 26% (5165/20 133) died, and 34% (6769/20 133) continued to receive care at the reporting date. 17% (3001/18 183) required admission to high dependency or intensive care units; of these, 28% (826/3001) were discharged alive, 32% (958/3001) died, and 41% (1217/3001) continued to receive care at the reporting date. Of those receiving mechanical ventilation, 17% (276/1658) were discharged alive, 37% (618/1658) died, and 46% (764/1658) remained in hospital. Increasing age, male sex, and comorbidities including chronic cardiac disease, non-asthmatic chronic pulmonary disease, chronic kidney disease, liver disease and obesity were associated with higher mortality in hospital.ConclusionsISARIC WHO CCP-UK is a large prospective cohort study of patients in hospital with covid-19. The study continues to enrol at the time of this report. In study participants, mortality was high, independent risk factors were increasing age, male sex, and chronic comorbidity, including obesity. This study has shown the importance of pandemic preparedness and the need to maintain readiness to launch research studies in response to outbreaks.Study registrationISRCTN66726260.
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
- Trang m1328
Laure Wynants, Ben Van Calster, Gary S. Collins, Richard D Riley, Georg Heinze, Ewoud Schuit, Elena Albu, Banafsheh Arshi, Vanesa Bellou, Marc J. M. Bonten, Darren Dahly, Johanna AAG Damen, Thomas P. A. Debray, Valentijn M. T. de Jong, Maarten De Vos, Paula Dhiman, Joie Ensor, Shan Gao, Maria Haller, Michael O. Harhay, Liesbet Henckaerts, Pauline Heus, Jeroen Hoogland, Mohammed T Hudda, Kevin Jenniskens, Michael Kammer, Nina Kreuzberger, Anna Lohmann, Kim Luijken, Jie Ma, Glen P. Martin, David J. McLernon, Constanza L. Andaur Navarro, Johannes B. Reitsma, Jamie C. Sergeant, Chunhu Shi, Nicole Skoetz, Luc Smits, Kym I E Snell, Matthew Sperrin, René Spijker, Ewout W. Steyerberg, Toshihiko Takada, Ioanna Tzoulaki, Sander M. J. van Kuijk, Bas C. T. van Bussel, Iwan C. C. van der Horst, Kelly Reeve, Florien S. van Royen, Jan Y Verbakel, Christine Wallisch, Jack Wilkinson, Robert Wolff, Lotty Hooft, Karel G.M. Moons, Maarten van Smeden
Abstract Objective To review and appraise the validity and usefulness of published and preprint reports of prediction models for prognosis of patients with covid-19, and for detecting people in the general population at increased risk of covid-19 infection or being admitted to hospital or dying with the disease. Design Living systematic review and critical appraisal by the covid-PRECISE (Precise Risk Estimation to optimise covid-19 Care for Infected or Suspected patients in diverse sEttings) group. Data sources PubMed and Embase through Ovid, up to 17 February 2021, supplemented with arXiv, medRxiv, and bioRxiv up to 5 May 2020. Study selection Studies that developed or validated a multivariable covid-19 related prediction model. Data extraction At least two authors independently extracted data using the CHARMS (critical appraisal and data extraction for systematic reviews of prediction modelling studies) checklist; risk of bias was assessed using PROBAST (prediction model risk of bias assessment tool). Results 126 978 titles were screened, and 412 studies describing 731 new prediction models or validations were included. Of these 731, 125 were diagnostic models (including 75 based on medical imaging) and the remaining 606 were prognostic models for either identifying those at risk of covid-19 in the general population (13 models) or predicting diverse outcomes in those individuals with confirmed covid-19 (593 models). Owing to the widespread availability of diagnostic testing capacity after the summer of 2020, this living review has now focused on the prognostic models. Of these, 29 had low risk of bias, 32 had unclear risk of bias, and 545 had high risk of bias. The most common causes for high risk of bias were inadequate sample sizes (n=408, 67%) and inappropriate or incomplete evaluation of model performance (n=338, 56%). 381 models were newly developed, and 225 were external validations of existing models. The reported C indexes varied between 0.77 and 0.93 in development studies with low risk of bias, and between 0.56 and 0.78 in external validations with low risk of bias. The Qcovid models, the PRIEST score, Carr’s model, the ISARIC4C Deterioration model, and the Xie model showed adequate predictive performance in studies at low risk of bias. Details on all reviewed models are publicly available at https://www.covprecise.org/ . Conclusion Prediction models for covid-19 entered the academic literature to support medical decision making at unprecedented speed and in large numbers. Most published prediction model studies were poorly reported and at high risk of bias such that their reported predictive performances are probably optimistic. Models with low risk of bias should be validated before clinical implementation, preferably through collaborative efforts to also allow an investigation of the heterogeneity in their performance across various populations and settings. Methodological guidance, as provided in this paper, should be followed because unreliable predictions could cause more harm than benefit in guiding clinical decisions. Finally, prediction modellers should adhere to the TRIPOD (transparent reporting of a multivariable prediction model for individual prognosis or diagnosis) reporting guideline. Systematic review registration Protocol https://osf.io/ehc47/ , registration https://osf.io/wy245 . Readers’ note This article is the final version of a living systematic review that has been updated over the past two years to reflect emerging evidence. This version is update 4 of the original article published on 7 April 2020 ( BMJ 2020;369:m1328). Previous updates can be found as data supplements ( https://www.bmj.com/content/369/bmj.m1328/related#datasupp ). When citing this paper please consider adding the update number and date of access for clarity.
Medical error—the third leading cause of death in the US
- Trang i2139
Martin A. Makary, Michael Daniel
A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance
- Trang n2061
Kathryn Skivington, Lynsay Matthews, Sharon Simpson, Peter Craig, Janis Baird, Jane Blazeby, Kathleen Boyd, Neil Craig, David French, Emma McIntosh, Mark Petticrew, Jo Rycroft‐Malone, Martin White, Laurence Moore
STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies
- Trang h5527
Patrick M. Bossuyt, Johannes B. Reitsma, David E Bruns, Douglas G. Altman, Paul Glasziou, Les Irwig, Jeroen G. Lijmer, David Moher, Drummond Rennie, Henrica C. W. de Vet, Herbert Y. Kressel, Nader Rifai, Robert Golub, Lotty Hooft, Daniël A. Korevaar, Jérémie F. Cohen